Advertisement

Topics

Latest "Transmission Blocking Malaria Vaccine" News Stories

10:20 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Transmission Blocking Malaria Vaccine" found in our extensive news archives from over 250 global news sources.

More Information about Transmission Blocking Malaria Vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Transmission Blocking Malaria Vaccine for you to read. Along with our medical data and news we also list Transmission Blocking Malaria Vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of Transmission Blocking Malaria Vaccine Companies for you to search.

Showing "Transmission Blocking Malaria Vaccine" News Articles 1–25 of 3,400+

Saturday 15th December 2018

The Wistar Institute Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryThe Wistar Institute Wistar is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer, infectious diseases, immunology and vaccine development. It also conducts research on genes, gene expression, and DNA biology; cancer biology; translational research; and virology. Wistar develops vaccines against rotavirus, r...


News digest – specialist prostate cancer scans, HPV vaccine catch up, breast cancer risk and surgery gel spray 

Science blog Specialist prostate cancer MRI scans recommended on NHS A type of specialist MRI scan has been recommended as one of the first tests for diagnosing people with suspected prostate cancer. Studies have found that using mpMRI could help 1 in 4 men with an abnormal PSA test or rectal exam avoid a biopsy. And for those who did need a biopsy, the scan can help to guide the procedure, m...

Friday 14th December 2018

Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite


[Comment] The changing epidemiology of mumps in a high vaccination era

The introduction of measles, mumps, and rubella (MMR) vaccine programmes has led to a dramatic reduction in all three infectious diseases globally. However, whereas measles and rubella remain under control wherever coverage is high, mumps outbreaks continue to flare up. Before universal vaccination, mumps was primarily a disease acquired during childhood and was characterised by fever and parotiti...

[Articles] A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study

The number of mumps outbreaks reported in recent years among highly vaccinated populations, including Indigenous populations, has been growing. More widespread and pre-emptive use of the third dose of measles, mumps, and rubella vaccine might be required to control and prevent future outbreaks in high-risk populations. Research should explore the benefit of increasing the intervals between vaccine...

Experimental HIV vaccine strategy works in non-human primates, research shows

For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human primates.

NACDS grant partners increase adult vaccination awareness

VLP Therapeutics gets $3.9 million grant from GHIT to further develop dengue vaccine

The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a US $3.9 million grant to further develop a novel tetravalent dengue virus─like particle vaccine.

Last winter’s dreadful #flu #season may have had a silver lining: Flu vaccine uptake rose sharply this fall in both children and adults. https://buff.ly/2Bkcknz 

Last winter’s dreadful #flu #season may have had a silver lining: Flu vaccine uptake rose sharply this fall in both children and adults. https://buff.ly/2Bkcknz 

Flu vaccinations rise sharply in both children and adults

Last winter’s dreadful flu season may have had a silver lining: Flu vaccine uptake rose sharply this fall in both children and adults.

Dec 14 2018 This Week in Cardiology

Carotid stents, more stem-cell retractions, AHA statement on statin safety, flu vaccine rules, medication errors, veterans care, and wasteful NIH research on golfing are discussed in this week’s podcast. theheart.org on Medscape

Higher Risk of Shingles Seen in Patients With Certain Cancers

(MedPage Today) -- Vaccine development may help with prevention of herpes zoster in this population

Pfizer Initiates Phase3 Program For 20-Valent Pneumococcal Conjugate Vaccine

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine or 20vPnC candidate, PF-06482077, for the prevention of i...

Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. “While the full extent of Prevenar 13 prot...

Drugs for Neglected Diseases initiative Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryDrugs for Neglected Diseases initiative DNDi is a nonprofit drug research and development RD organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis HAT, or sleeping sickness, leishmaniasis, and Chagas disease, and conducts research and development projects ...

Commercial opportunities for emerging infectious diseases vaccine developers

Although development of interventions for emerging infectious diseases (EIDs) has traditionally been limited by a lack of market incentives, novel funding mechanisms and global partnerships for outbreak preparedness are expanding the commercial prospects for vaccine developers, according to analytics company GlobalData

Experimental HIV vax works in primates

Scientists at Scripps Research have published new research that shows that their experimental vaccine strategy works in non-human primates.

An assembly-line-style test found thousands of compounds that hold promise for halting the malaria parasite’s spread through the body #ResearchHighlight https://go.nature.com/2rysCV8 

An assembly-line-style test found thousands of compounds that hold promise for halting the malaria parasite’s spread through the body #ResearchHighlight https://go.nature.com/2rysCV8 

Ebola: How Many Must Die Before WHO Acts? asks AHF

WHO and Merck must do more to ensure vaccines are available and that healthcare workers are protected throughout the Congo, where the second worst Ebola outbreak in history has killed almost 300 people and has reached a major population center. With the world’s second worst Ebola outbreak in history recently spreading to a major city in the Democrati...

Generex Biotechnology Corp GNBT Medical Equipment Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryGenerex Biotechnology Corp Generex carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the in...

Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the ...

Media:Jessica Smith(212) 733-6213jessica.m.smith@pfizer.comorInvestors:Ryan Crowe(212) 733-8160ryan.crowe@pfizer.com Read more...

Thursday 13th December 2018

Italian scientists protest funding for vaccine-safety investigation

Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone

HIV vaccine protects non-human primates from infection

(Scripps Research Institute) New research shows that an experimental HIV vaccine strategy works in non-human primates. In the study, rhesus macaque monkeys produced neutralizing antibodies against one strain of HIV that resembles the resilient viral form that most commonly infects people, called a Tier 2 virus.

[Comment] Understanding tuberculosis transmission might be the gamechanger we need

Despite being a familiar and ancient disease, tuberculosis has the ignominy of also being the leading infectious cause of death.1 Although there are many complex reasons for this unenviable position, a notable one is that much about it is still unknown. The main thrust of the response to the tuberculosis epidemic has been attempts to refine existing therapies and to develop new drugs and diagnosti...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks